What is Profluent Bio?
Headquartered in Berkeley, California, Profluent Bio operates at the intersection of machine learning and synthetic biology. The company specializes in developing AI-first generative models that enable the de novo design of proteins with specific, functional properties. By moving beyond the limitations of natural protein evolution, Profluent aims to address critical challenges in human health, offering a scalable solution for the development of next-generation therapeutics. Its market position is defined by its ability to integrate high-throughput validation with predictive modeling, effectively shortening the development cycle for complex biological molecules.
How much funding has Profluent Bio raised?
Profluent Bio has raised a total of $141M across 2 funding rounds:
Other Financing Round
$35M
Other Financing Round
$106M
Other Financing Round (2024): $35M with participation from Insight Partners, Air Street Capital, and Spark Capital
Other Financing Round (2025): $106M led by Bezos Expeditions, Altimeter Capital, Insight Partners, and Spark Capital
Key Investors in Profluent Bio
Bezos Expeditions
An investment firm founded by Jeff Bezos that focuses on a diverse range of sectors including technology, healthcare, and space exploration, known for supporting innovative companies with long-term growth potential.
Altimeter Capital
An investment firm that partners with technology companies from early growth through public markets, managing concentrated portfolios to support product strategy and durable value creation.
Insight Partners
A global firm that invests in high-growth software and technology companies, providing capital and hands-on operational support to help businesses scale from early stage to IPO.
What's next for Profluent Bio?
With the successful closure of this major enterprise-level funding round, Profluent Bio is poised to transition from a research-intensive startup to a clinical-stage powerhouse. The strategic roadmap likely includes the expansion of its computational infrastructure, the recruitment of specialized talent in bioinformatics and protein engineering, and the acceleration of internal drug discovery programs. Furthermore, the company is expected to leverage its deep-pocketed investor base to forge strategic partnerships with established pharmaceutical entities, thereby validating its platform's utility in real-world clinical applications. As the firm continues to refine its generative models, the focus will shift toward demonstrating the safety and efficacy of its designed proteins in preclinical models, a critical step toward long-term commercial viability.
See full Profluent Bio company page
